Brief: Medivir Receives Positive Opinion On Orphan Medicinal Drug Designation By The European Medicines Agency For Miv-818

Medivir AB

30/04/2020 07:32

April 30 (Reuters) - Medivir AB  MVIRb.ST :
    * MEDIVIR RECEIVES POSITIVE OPINION ON ORPHAN MEDICINAL DRUG DESIGNATION BY THE EUROPEAN
MEDICINES
AGENCY FOR MIV-818
    * MEDIVIR - RECEIVED POSITIVE OPINION FROM COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS ON ORPHAN
MEDICINAL PRODUCT DESIGNATION IN EU FOR MIV-818
    * MEDIVIR - MIV-818 FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC), MOST
COMMON
TYPE OF PRIMARY LIVER CANCER.

Source text for Eikon:  ID:nWkr5sn8KV 
Further company coverage:  MVIRb.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))